» Articles » PMID: 2395886

2,3,7,8-Tetrachlorodibenzo-p-dioxin Causes an Extensive Alteration of 17 Beta-estradiol Metabolism in MCF-7 Breast Tumor Cells

Overview
Specialty Science
Date 1990 Sep 1
PMID 2395886
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

MCF-7 breast tumor cells form multicellular foci in vitro when supplemented with 17 beta-estradiol (E2). In the presence of E2 and the aryl hydrocarbon-receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), MCF-7 cells grow to confluence but do not form foci. To investigate the role of E2 metabolism in this antiestrogenic effect of TCDD, analyses were performed by capillary GC/MS. The results revealed that pretreatment of MCF-7 cultures with TCDD (10 nM) rapidly depletes E2. In untreated cultures supplemented with 10 nM E2, the concentration of free E2 decreased to 4 nM in the first 12 hr, followed by a slower rate of decline. After 3 days most E2 in the medium was in conjugated form(s); 1.7 nM was present as free E2, and 2.9 nM was released by treatment with glucuronidase/sulfatase. In TCDD-treated cultures, E2 declined to 290 pM in 12 hr and after 2 days was not detected (less than 100 pM) either as free steroid or after treatment with glucuronidase/sulfatase. Intracellular E2 and estrone were likewise depleted by pretreatment with TCDD. Microsomes from TCDD-treated cells showed highly elevated aryl hydrocarbon-hydroxylase activity and catalyzed hydroxylations of E2 at C-2, C-4, C-15 alpha, and C-6 alpha with a combined rate of 0.85 nmol/min per nmol of cytochrome P-450 at saturating E2. These results suggest that depletion of E2 by enhanced metabolism accounts for the antiestrogenic activity of TCDD in MCF-7 cells.

Citing Articles

Adipose Tissue as a Site of Toxin Accumulation.

Jackson E, Shoemaker R, Larian N, Cassis L Compr Physiol. 2017; 7(4):1085-1135.

PMID: 28915320 PMC: 6101675. DOI: 10.1002/cphy.c160038.


Endocrine Disrupting Chemicals and Endometrial Cancer: An Overview of Recent Laboratory Evidence and Epidemiological Studies.

Mallozzi M, Leone C, Manurita F, Bellati F, Caserta D Int J Environ Res Public Health. 2017; 14(3).

PMID: 28327540 PMC: 5369169. DOI: 10.3390/ijerph14030334.


Induction of expression of aryl hydrocarbon receptor-dependent genes in human HepaRG cell line modified by shRNA and treated with β-naphthoflavone.

Brauze D, Zawierucha P, Kiwerska K, Bednarek K, Oleszak M, Rydzanicz M Mol Cell Biochem. 2016; 425(1-2):59-75.

PMID: 27796684 PMC: 5225230. DOI: 10.1007/s11010-016-2862-3.


The Aryl Hydrocarbon Receptor: A Target for Breast Cancer Therapy.

Powell J, Goode G, Eltom S J Cancer Ther. 2014; 4(7):1177-1186.

PMID: 25068070 PMC: 4111475. DOI: 10.4236/jct.2013.47137.


Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Safe S, Lee S, Jin U Toxicol Sci. 2013; 135(1):1-16.

PMID: 23771949 PMC: 3748760. DOI: 10.1093/toxsci/kft128.


References
1.
JELLINCK P, Fishman J . Activation and irreversible binding of regiospecifically labeled catechol estrogen by rat liver microsomes: evidence for differential cytochrome P-450 catalyzed oxidations. Biochemistry. 1988; 27(16):6111-6. DOI: 10.1021/bi00416a042. View

2.
Romkes M, Safe S . Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic and uterine estrogen receptor levels in rats. Toxicol Appl Pharmacol. 1987; 87(2):306-14. DOI: 10.1016/0041-008x(87)90292-4. View

3.
Adams J, Phillips N, Hall R . Metabolic fate of estradiol in human mammary cancer cells in culture: estrogen sulfate formation and cooperativity exhibited by estrogen sulfotransferase. Mol Cell Endocrinol. 1988; 58(2-3):231-42. DOI: 10.1016/0303-7207(88)90159-1. View

4.
Vickers P, Dufresne M, Cowan K . Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. Mol Endocrinol. 1989; 3(1):157-64. DOI: 10.1210/mend-3-1-157. View

5.
Fisher B, Costantino J, Redmond C, POISSON R, Bowman D, Couture J . A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320(8):479-84. DOI: 10.1056/NEJM198902233200802. View